Investment Trusts

International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

Actions
  • Price (GBX)618.00
  • Today's Change2.00 / 0.32%
  • Shares traded58.85k
  • 1 Year change-7.21%
  • Beta0.1829
Data delayed at least 20 minutes, as of May 01 2024 16:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Total returns on £1000

1Y
Fund/benchmarkChange
PriceInternational Biotechnology Trust (Ordinary Share)-2.67%
NAVInternational Biotechnology Trust (Ordinary Share)-0.32%
Morningstar's BenchmarkNasdaq Biotechnology Index--

Key statistics

On Wednesday, International Biotechnology Trust (IBT:LSE) closed at 618.00, 12.77% above the 52 week low of 548.00 set on Oct 27, 2023.
52-week range
Today
548.00Oct 27 2023704.00Feb 28 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding37.74m
Market cap232.28m GBP
Total assets283.62m GBP
Total expense ratio1.44%
High618.00
Low612.00
Previous close616.00
Average volume48.06k
YTD Change-3.74%
Beta0.1829
Diluted NAV (est)689.81
Diluted NAV (last pub)684.74
Premium/Discount-10.60%
Net Gearing+10.01%
Annual div (ADY)28.10
GBX
Annual div yield (ADY)4.56%
Div ex-dateDec 21 2023
Div pay-dateJan 26 2024
Data delayed at least 20 minutes, as of May 01 2024 16:28 BST.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.